Floatz logo

Riluzole

Amyotrophic Lateral Sclerosis

AB ScienceSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
73/ 100

Competitive context

150 Active assets in the Amyotrophic Lateral Sclerosis cohort.

Asset / SponsorPhaseRating
TAURURSODIOL
Amylyx Pharmaceuticals Inc.
Phase 3BBB
Tofersen
Biogen
Phase 4BBB
Mexiletine
Bjorn Oskarsson, MD
Phase 4BB
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II)
Collaborative Medicinal Development Pty Limited
Phase 2/3BB
Mci-186
Tanabe Pharma Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

Riluzole is also rated in:

major depressive disorderDormant
BB
Indicative ·
68 / 100
View asset →
cerebellar ataxiaDormant
BB
Indicative ·
66 / 100
View asset →
inflammatory diseaseDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →